CU20160183A7 - Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida - Google Patents

Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida

Info

Publication number
CU20160183A7
CU20160183A7 CUP2016000183A CU20160183A CU20160183A7 CU 20160183 A7 CU20160183 A7 CU 20160183A7 CU P2016000183 A CUP2016000183 A CU P2016000183A CU 20160183 A CU20160183 A CU 20160183A CU 20160183 A7 CU20160183 A7 CU 20160183A7
Authority
CU
Cuba
Prior art keywords
pyrimidin
salts
morpholinophenylamino
cyanomethyl
benzamide
Prior art date
Application number
CUP2016000183A
Other languages
English (en)
Inventor
Brandon H Brown
Ernest A Carra
Jeffrey N Hemenway
Henry Morrison
Troy Reynolds
Bing Shi
Dimitrios Stefanidis
Fang Wang
Matthew Robert Warr
James Andrew Whitney
Yan Xin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160183(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CU20160183A7 publication Critical patent/CU20160183A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas nuevas de N-(cianometil)-4-(2-(4 morfolinofenilamino)pirimidin-4-il)benzamida (CYT-387) como inhibidores de la quinasa JAK específicamente a la forma I anhidra del monoclorhidrato de N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida y la forma III anhidra del monoclorhidrato de N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida; las cuales tienen estabilidad incrementada respecto otras sales o formas de CYT-387 en ciertas condiciones. La presente invención también proporciona composiciones, incluyendo composiciones farmacéuticas, kits que incluyen los compuestos, y métodos para usar y preparar las composiciones farmacéuticas, las cuales son útiles en el tratamiento de enfermedades, trastornos o afecciones mediadas por JAK.
CUP2016000183A 2014-06-12 2016-12-09 Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida CU20160183A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
PCT/US2015/035316 WO2015191846A1 (en) 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Publications (1)

Publication Number Publication Date
CU20160183A7 true CU20160183A7 (es) 2017-05-10

Family

ID=53674249

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000183A CU20160183A7 (es) 2014-06-12 2016-12-09 Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida

Country Status (36)

Country Link
US (5) US9469613B2 (es)
EP (3) EP3719005A1 (es)
JP (5) JP6600649B2 (es)
KR (1) KR101928225B1 (es)
CN (2) CN110627728A (es)
AP (1) AP2016009551A0 (es)
AR (1) AR100818A1 (es)
AU (1) AU2015274554B9 (es)
BR (1) BR112016028749A2 (es)
CA (1) CA2951883C (es)
CR (1) CR20160575A (es)
CU (1) CU20160183A7 (es)
CY (2) CY1123604T1 (es)
DK (1) DK3154950T3 (es)
EA (1) EA032639B1 (es)
EC (1) ECSP16093323A (es)
ES (1) ES2822773T3 (es)
FI (1) FIC20240025I1 (es)
FR (1) FR24C1030I2 (es)
HR (1) HRP20201492T1 (es)
HU (2) HUE051360T2 (es)
IL (3) IL249038B (es)
LT (2) LT3154950T (es)
MA (1) MA40067A (es)
MX (3) MX374541B (es)
NL (1) NL301282I2 (es)
NZ (1) NZ725966A (es)
PH (1) PH12016502461A1 (es)
PL (1) PL3154950T3 (es)
PT (1) PT3154950T (es)
RS (1) RS61065B1 (es)
SG (2) SG10201911925TA (es)
SI (1) SI3154950T1 (es)
TW (3) TWI681954B (es)
UY (1) UY36166A (es)
WO (1) WO2015191846A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
WO2019218958A1 (zh) * 2018-05-15 2019-11-21 江苏豪森药业集团有限公司 包含小分子egfr抑制剂的药物组合物及其制备方法
CN113015527A (zh) 2018-08-21 2021-06-22 西拉肿瘤学公司 治疗骨髓纤维化的血小板计数诊断方法
KR20210145735A (ko) * 2019-02-12 2021-12-02 임팩트 바이오메디신스, 인코포레이티드 Jak2 저해제의 결정질 형태
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
EP4376849A1 (en) 2021-07-30 2024-06-05 GlaxoSmithKline LLC Biomarker and patient selection in treatment for myelofibrosis
CA3228524A1 (en) 2021-08-10 2023-02-16 Bryan William STROUSE Momelotinib combination therapy
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
WO2023056935A1 (zh) * 2021-10-09 2023-04-13 广东东阳光药业有限公司 抗纤维化组合物
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
US6949544B2 (en) 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
IL160799A0 (en) 2001-09-12 2004-08-31 Virexx Medical Corp Vascular occlusion solid-phase agent with immobilised platelet binding agent
IL165264A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Protein kinase inhibitors
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
WO2004041789A1 (en) 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
EP1562938B1 (en) 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
JP2006508107A (ja) 2002-11-05 2006-03-09 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼのインヒビターとして有用な化合物
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
JP2007500179A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
HRP20161751T1 (hr) 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
TW200626559A (en) 2004-10-13 2006-08-01 Wyeth Corp Anilino-pyrimidine analogs
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
AU2007220047B2 (en) 2006-02-28 2013-08-01 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
CN104030990B (zh) * 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
CA2698511C (en) 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
US20100310563A1 (en) 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
US20110269721A1 (en) 2008-08-05 2011-11-03 Targegen, Inc. Methods of treating thalassemia
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010141946A1 (en) 2009-06-05 2010-12-09 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
EA201391591A1 (ru) * 2011-05-02 2014-12-30 Им Байосайенсиз Аустралиа Пти Лтд. Лечение множественной миеломы
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
WO2014051056A1 (ja) * 2012-09-28 2014-04-03 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
AU2014205472B2 (en) 2013-01-09 2018-05-10 Concert Pharmaceuticals Inc. Deuterated momelotinib
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI681954B (zh) * 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Also Published As

Publication number Publication date
JP2021107465A (ja) 2021-07-29
EA201692356A1 (ru) 2017-07-31
CN106458929A (zh) 2017-02-22
SG10201911925TA (en) 2020-01-30
TWI729644B (zh) 2021-06-01
JP2023021454A (ja) 2023-02-10
MX374541B (es) 2025-03-06
KR101928225B1 (ko) 2018-12-11
MX2016016294A (es) 2017-09-01
MX2019009564A (es) 2019-10-02
US9469613B2 (en) 2016-10-18
KR20170015496A (ko) 2017-02-08
IL276948A (en) 2020-10-29
JP2018184486A (ja) 2018-11-22
AU2015274554B9 (en) 2018-04-19
IL249038B (en) 2020-09-30
IL276948B (en) 2021-09-30
JP2017517535A (ja) 2017-06-29
PL3154950T3 (pl) 2021-01-25
US20150361050A1 (en) 2015-12-17
EP3907219A1 (en) 2021-11-10
US9809559B2 (en) 2017-11-07
ES2822773T3 (es) 2021-05-04
EP3154950A1 (en) 2017-04-19
HUS2400025I1 (hu) 2024-08-28
WO2015191846A1 (en) 2015-12-17
HUE051360T2 (hu) 2021-03-01
NZ725966A (en) 2018-04-27
SG11201610079VA (en) 2016-12-29
EP3719005A1 (en) 2020-10-07
USRE48285E1 (en) 2020-10-27
AU2015274554A1 (en) 2016-11-24
BR112016028749A2 (pt) 2017-08-22
UY36166A (es) 2016-01-29
AP2016009551A0 (en) 2016-11-30
HRP20201492T1 (hr) 2021-01-08
PT3154950T (pt) 2020-10-09
JP7550205B2 (ja) 2024-09-12
TW202134236A (zh) 2021-09-16
PH12016502461A1 (en) 2017-03-06
IL249038A0 (en) 2017-01-31
JP2020059759A (ja) 2020-04-16
CA2951883C (en) 2020-05-05
TW202012378A (zh) 2020-04-01
CN110627728A (zh) 2019-12-31
EP3154950B1 (en) 2020-08-05
CY2024024I2 (el) 2025-03-28
CR20160575A (es) 2017-01-20
DK3154950T3 (da) 2020-09-14
IL286442A (en) 2021-10-31
FR24C1030I1 (fr) 2024-08-30
JP7198867B2 (ja) 2023-01-04
MA40067A (fr) 2015-12-17
JP6600649B2 (ja) 2019-10-30
CA2951883A1 (en) 2015-12-17
JP6840909B2 (ja) 2021-03-10
TW201617323A (zh) 2016-05-16
CY2024024I1 (el) 2025-03-28
LTPA2024523I1 (es) 2024-07-25
FIC20240025I1 (fi) 2024-07-12
AU2015274554B2 (en) 2018-02-15
JP6883560B2 (ja) 2021-06-09
USRE50497E1 (en) 2025-07-22
MX2022015558A (es) 2023-01-30
AR100818A1 (es) 2016-11-02
USRE49445E1 (en) 2023-03-07
LT3154950T (lt) 2020-11-25
US20160347719A1 (en) 2016-12-01
EA032639B1 (ru) 2019-06-28
FR24C1030I2 (fr) 2025-06-13
SI3154950T1 (sl) 2021-01-29
RS61065B1 (sr) 2020-12-31
ECSP16093323A (es) 2017-01-31
CY1123604T1 (el) 2022-03-24
NL301282I2 (nl) 2025-03-12
TWI681954B (zh) 2020-01-11

Similar Documents

Publication Publication Date Title
CU20160183A7 (es) Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
ECSP18018869A (es) Sales de un inhibidor de lsd1
MX2020008024A (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
ECSP16067303A (es) Heteroarilos y usos de estos
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY37205A (es) Inhibidores de bromodominios
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CO7380758A2 (es) Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
ECSP18026386A (es) Sales de un inhibidor de pim quinasa
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
UY35393A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
MX2017009696A (es) Formas cristalinas de c21h22cl2n4o2.